Busy. Please wait.
or

show password
Forgot Password?

Don't have an account?  Sign up 
or

Username is available taken
show password

why


Make sure to remember your password. If you forget it there is no way for StudyStack to send you a reset link. You would need to create a new account.
We do not share your email address with others. It is only used to allow you to reset your password. For details read our Privacy Policy and Terms of Service.


Already a StudyStack user? Log In

Reset Password
Enter the associated with your account, and we'll email you a link to reset your password.

Remove Ads
Don't know
Know
remaining cards
Save
0:01
To flip the current card, click it or press the Spacebar key.  To move the current card to one of the three colored boxes, click on the box.  You may also press the UP ARROW key to move the card to the "Know" box, the DOWN ARROW key to move the card to the "Don't know" box, or the RIGHT ARROW key to move the card to the Remaining box.  You may also click on the card displayed in any of the three boxes to bring that card back to the center.

Pass complete!

"Know" box contains:
Time elapsed:
Retries:
restart all cards




share
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.

  Normal Size     Small Size show me how

1-Anticoagulant

TermDefinition
Low-molecular-weight heparin : # Enoxaparin, Daltaparin & Tinzaparin # isolated from UFH
Mechanism of action of LMWHs: #greater ability than UFH to inactivate factor Xa # lesser incidence to cause bleeding # lesser incidence to cause thrombocytopenia
Advantages of LMWHs: 1- LMWH have low affinity for plasma proteins 90% bioavailability > 30% bioavailability higher SC bioavailability 2-LMWH effect is more predictable than UFH 3-have longer duration of action 4-lab. monitoring unnecessary 5-a lower incidenc
Therapeutic uses of LMWH: - Prevention of DVT following surgery - Prevention of ischemic complications - Treatment of established DVT
Side effects of LMWH: # Bleeding < than UFH # Immune-mediated thrombocytopenia < than UFH # Cost > UFH
Fondaparinux: - (SC) route - pentasaccharide structure of fondaparinux - selective inhibition of Xa as LMWH
Pharmacokinetics: as LMWH Fondaparinux - Fondaparinux has a predictable PH. profile - Fondaparinux requires less monitoring than heparin -Fondaparinux is eliminated in urine mainly as unchanged → contraindicated in patients with severe renal impairment
Therapeutic uses of fondaparinux : - Prevention of DVT - Treatment of acute DVT & acute PE (with Warfarin) - “As alternative” for the treatment of ACS SE--Bleeding
Direct Thrombin Inhibitors (DTIs): Parenteral: as Lepirudin, Bivalirudin Oral : as Argatroban, Dabigatran all bind to & block thrombin(IIa) directly at its “active site"
univalent” thrombin inhibitors: as argatroban & dabigatran &bivalirudin only bind at the “active site”→ bind thrombin reversibly
bivalent” thrombin inhibitors bind at 2 binding sites “active site & exosite 1 bind thrombin irreversibly //DTIs effect on soluble thrombin (IIa) & fibrin-bound thrombin
Lepirudin: -independent of AT III & no effects on factor Xa -directly& irreversibly inactivates IIa -Administered IV & cleared by the kidneys -Argatoban alternative in renal dysfunction -aPTT monitoring -anticoagulants in HIT -bleeding → no antidote is avail
Bivalirudin -administered IV & has rapid onset&offset -alternative to heparin in HIT in coronary angioplasty or cardiopulmonary bypass surgery
Dabigatran : -1st oral anticoagulant -does not require routine monitoring - few drug-drug interactions compared to warfarin - prevention of thromboembolism in patients with AF
Oral anticoagulants: Warfarine -Active in vivo only -Vitamin K antagonists -
Clotting factors → II, VII, IX , X & protein C &S are dependent upon vitamin K for their synthesis in the liver
vitamin K to a newborn why newborns get a Vit K shot → to avoid ”hemorrhagic disease of the newborn”
Oral anticoagulants: Warfarine -Active in vivo only -Vitamin K antagonists -
Clotting factors → II, VII, IX , X & protein C &S are dependent upon vitamin K for their synthesis in the liver
vitamin K to a newborn why newborns get a Vit K shot → to avoid ”hemorrhagic disease of the newborn”
Mechanism of action of warfarin: Warfarin is structurally similar to vitamin K & competitively inhibit epoxide reductase -inhibits the synthesis but not the actions of these 4 clotting factors
Onset of action of warfarin: -There is a delay in the onset & duration of anti-coagulant effect -Usually 48-72 hours to achieve its full effects - the onset of action of warfarin depends on the limination half-lives of the already formed -
Pharmacokinetics of Warfarin: -Absorption: completely absorbed by the GIT -Food interferes with the absorption of Warfarin - Distribution: highly protein bound (98-99%) - Metabolism & excretion: cytochrome P450 enzymes of the liver
Therapeutic uses of Warfarin: - Prophylaxis:in atrial fibrillation (AF), post-prosthetic heart valve replacement , previous DVT , repeated PE -Treatment of established DVT , PE -used for long-term anticoagulation
Side effects of Warfarin : 1- Bleeding (especially in GIT) is the most common side effect 2- Cutaneous reactions: Warfarin-induced purple toe syndrome & skin necrosis 3-Fetal hemorrhage & teratogenenic .
Target INR when use Warfarin in: Prophylaxis of DVT )INR 2-2.5) Treatment of DVT&PE, AF , mural thrombus following MI ( INR 2.5) Recurrent DVT & PE, mechanical prosthetic heart valve (INR 3.5)
Warfarin antidote: -1st step to stop Warfarin administration - Reversal of Warfarin effects by: → Vitamin K1 (phytonadione) oral, IV → several hours to act → emergency or urgent cases → to replace the deficient clotting factors→blood replacement ,PCC ,FFP
large number of pharmacokinetic & pharmacodynamic drug-drug interactions with warfarin activity
Created by: ahmad445